Results 111 to 120 of about 54,010 (241)
Pancreatic Cancer—Advances in the Last 50 Years
World Journal of Surgery, EarlyView.
S. George Barreto +5 more
wiley +1 more source
What's new? Colorectal cancer (CRC) is increasingly complicated by drug‐resistant tumors that limit the effectiveness of anticancer therapies. Because resistance mechanisms vary among patients and can evolve over time, personalized treatment strategies are needed.
Keren Zohar +16 more
wiley +1 more source
Irinotecan in combination with new agents
Today, irinotecan in combination with bolus and/or infusional 5-FU/FA constitutes a standard first-line treatment for patients with metastatic colorectal cancer. In an attempt to further improve clinical outcome, the use of irinotecan in combination with
JL Van Laethem +16 more
core +1 more source
Although existing research suggests a limited relationship between survival outcomes and radiological response rates in children with newly diagnosed rhabdomyosarcoma, there is little evidence in the relapsed/refractory setting. Using aggregate data collected from the Living‐REFoRMS dataset of early‐phase trials, the authors established that ...
Preethi Muthukumar +4 more
wiley +1 more source
Peritoneal metastases (PM) are common in patients with colorectal cancer. Patients with PM have a poor prognosis, and for those who are not eligible for cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC ...
Pascale C. S. Rietveld +9 more
doaj +1 more source
ABSTRACT Background 131I‐metaiodobenzylguanidine (131I‐MIBG) radiotherapy is a key treatment for relapsed and refractory (R/R) neuroblastoma (NB). Patients with R/R disease treated in the modern era are increasingly exposed to anti‐GD2 immunotherapy, which exerts selective pressure and may modify both tumor cell state and microenvironment.
Benjamin J. Lerman +7 more
wiley +1 more source
Supplementary Material for: Irinotecan-Induced Dysarthria
Colorectal carcinomas are among the most common tumor types and are generally treated with palliative chemotherapy in case of metastatic disease. Here, we describe the case of a 46-year-old patient with metastatic rectal carcinoma who received second ...
van der Vliet H.J. (4131472) +4 more
core +1 more source
ABSTRACT Background Wilms tumor (WT) treatment imposes a significant time burden on patients and their families. Time toxicity is a patient‐centered metric that quantifies the burden of healthcare interaction. We sought to define time toxicity in the first year after diagnosis of WT and hypothesized that it would increase as tumor stage and treatment ...
Caleb Q. Ashbrook +6 more
wiley +1 more source
IntroductionThe aim of this study was to provide a review of the clinical evidence for use of ramucirumab (RAM) plus folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan (FOLFIRI) or irinotecan as second-line treatment in gastroesophageal ...
Haeseong Park +8 more
doaj +1 more source
What's New? The emerging role of immunotherapy in small‐cell lung cancer treatment has not been fully elucidated, particularly outside of clinical trials. This single‐center retrospective cohort study examined real‐world treatment patterns and overall survival in South Korea during the 2018–2023 period.
Sehhoon Park +11 more
wiley +1 more source

